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Abstract
Background:  The mechanism(s) of nociceptive dysfunction and potential roles of opioid
neurotransmitters are unresolved in the chronic pain syndromes of fibromyalgia and chronic low
back pain.
Methods: History and physical examinations, tender point examinations, and questionnaires were
used to identify 14 fibromyalgia, 10 chronic low back pain and 6 normal control subjects. Lumbar
punctures were performed. Met-enkephalin-Arg6-Phe7 (MEAP) and nociceptin immunoreactive
materials were measured in the cerebrospinal fluid by radioimmunoassays.
Results: Fibromyalgia (117.6 pg/ml; 85.9 to 149.4; mean, 95% C.I.; p = 0.009) and low back pain
(92.3 pg/ml; 56.9 to 127.7; p = 0.049) groups had significantly higher MEAP than the normal control
group (35.7 pg/ml; 15.0 to 56.5). MEAP was inversely correlated to systemic pain thresholds.
Nociceptin was not different between groups. Systemic Complaints questionnaire responses were
significantly ranked as fibromyalgia > back pain > normal. SF-36 domains demonstrated severe
disability for the low back pain group, intermediate results in fibromyalgia, and high function in the
normal group.
Conclusions:  Fibromyalgia was distinguished by higher cerebrospinal fluid MEAP, systemic
complaints, and manual tender points; intermediate SF-36 scores; and lower pain thresholds
compared to the low back pain and normal groups. MEAP and systemic pain thresholds were
inversely correlated in low back pain subjects. Central nervous system opioid dysfunction may
contribute to pain in fibromyalgia.
Background
Fibromyalgia (FM) is an enigmatic condition character-
ized by increased complaints of widespread pain with ten-
derness to palpation [1]. The tenderness is traditional
tested by manually pressing over so-called tender points,
but more recent studies have shown that the tenderness is
generalized phenomenon [2]. The mechanisms responsi-
ble for the increase in the perception of pain in FM, and
the variation of pain sensitivity in the general population
are unclear. A similar continuum is seen with heat –
induced pain. However, when subjects who report pain to
a minimal stimulus (low pain threshold) were compared
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to subjects reporting less pain with the same stimulus
(high pain threshold), there was enhanced functional
magnetic resonance imaging (fMRI) responses in the low
pain threshold group [3]. The differences in activation
were greatest in the primary somatosensory cortex, ante-
rior cingulate cortex and prefrontal cortex. These fMRI pat-
terns suggest there may be a continuum within the
population for pain thresholds, central cortical activation
and verbalized pain perception. These results may be
applicable to FM since the same brain regions have been
identified in response to painful stimuli [4].
The pain present in FM may induce antinociceptive neural
mechanisms with the release of opioid peptides. This
hypothesis was tested by measuring opioid peptides in
cerebrospinal fluid, and comparing these levels to sys-
temic pain thresholds, subjective complaints, and quality
of life measures in 3 sets of volunteers. FM and Chronic
Fatigue Syndrome often overlap [5]. Chronic Fatigue Syn-
drome is characterized by severe fatigue associated with
exertional exhaustion, pain symptoms, neurocognitive
and sleep dysfunction [6]. Therefore, opioid levels were
compared for FM and FM/ Chronic Fatigue Syndrome
subsets. The second group had chronic low back pain
(LBP) without FM or Chronic Fatigue Syndrome. These
subjects have a chronic regional pain syndrome [7] and
served as a positive control group. The negative control
group was formed by healthy persons with no pain or
fatigue.
Two peptides were selected for measurements because
they were involved in antinociceptive responses. Alterna-
tively, dysfunction of their release could predispose to
chronic pain. Preproenkephalin A is the precursor for leu-
cine-enkephalin, methionine-enkephalin (Met-enk), Met-
enk-Arg6-Gly7-Leu8, and Met-enk-Arg6-Phe7 (MEAP) [8].
MEAP was elevated in many brain regions in inflamma-
tory models of arthritis and gluteal carregeenan injection
in rats [9,10]. Nociceptin, also known as orphanin FQ,
was increased in the cingulate gyrus in rat chronic pain
models [9].
Methods
Subjects
FM, LBP and Normal control subjects between the ages of
18 and 70 years were recruited to this IRB-approved pro-
tocol from rheumatology and orthopedics clinics, adver-
tisements, and word of mouth. Normal subjects were pain
and chronic fatigue free, had no diabetic, neurologic,
inflammatory, autoimmune, or other chronic disorder
that could predispose to pain, alterations in sensation, or
known variations in cerebrospinal fluid composition. LBP
inclusion criteria were (i) dominant pain complaint of
low back pain, and (ii) imaging studies within the past 6
months. Exclusion criteria were: (a) evidence of a lumbar
fracture or tumor to explain the pain, (b) any chronic ill-
ness that may affect functional status such as diabetes,
cancer, chronic obstructive pulmonary disease, chronic
inflammatory diseases, renal insufficiency or similar
debilitating disorders, (c) previous back or neck surgery,
and (d) FM or Chronic Fatigue Syndrome. FM subjects
had a prior clinical diagnosis of FM including widespread
pain affecting all 4 quadrants and the axial skeleton last-
ing at least 3 months that was not explained by any other
chronic illness, and the presence of at least 11 of 18 tender
points when manual, digital pressure of ~4 kg was applied
[1]. All subjects were medication-free for at least 4 days
prior to study. Subjects participated in a 1/2 day protocol
that involved confirmatory history and physical examina-
tion, questionnaires, tender point examinations, and lum-
bar puncture.
Questionnaires
Systemic complaints questionnaire
This self – report questionnaire containing 44 queries
grouped into the following modules: (i) Fatigue; (ii) Mus-
culoskeletal: morning stiffness, muscle pain, muscle
spasms, dry eyes, dry mouth, fingers sensitive to the cold,
fingers turn blue and/or white in the cold, swollen lymph
nodes, swollen joints, fever; (iii) Chest: shortness of
breath (SOB), SOB when hurrying on level ground or
walking up a slight hill, SOB when walking with other
people of own age on level ground, stop for breath when
walking at own pace on level ground, SOB when washing
or dressing, rapid heart rate, chest pain, irregular heart
rate, palpitations; (iv) Headaches: migraine or tension
type; (v) Neurological: numbness or tingling of hands or
legs, inability to concentrate, problems with memory, diz-
ziness; (v) Ear, Nose and Throat (ENT): problems with
balance, hearing loss, ear pain, sensation of ear blockage
or fullness, ringing in the ears, sinus pain; (vi) Bladder:
urinary urgency, pelvic discomfort / pain / pressure, per-
sistent bladder fullness after urination, dysuria; and (vii)
Irritable Bowel Syndrome (Rome I criteria): abdominal
pain relieved with bowel movement, abdominal pain
with a change in frequency or consistency of stool,
changes in stool consistency, changes in stool form (hard
or loose/watery), changes in passing of stool, bloating or
feeling of abdominal distention, passage of mucus, nau-
sea or vomiting [11]. Subjects were asked to respond "Yes"
if they had recurrent or chronic symptoms for more than
3 of the past 12 months. The sum of positive responses for
each module and the total were determined.
Subjects completed the MOS SF-36[12]. The domains
were Physical Functioning (PF), Social Functioning (SF),
Role Limitation due to Physical Problems (PP), Role Lim-
itation due to Emotional Problems (EP), Mental Health
(MH), Energy / Fatigue (E/F), Pain (P), General Percep-
tion of Health (GP) and Change in Health (CH).BMC Musculoskeletal Disorders 2004, 5:48 http://www.biomedcentral.com/1471-2474/5/48
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Pain threshold and tender point examinations
All subjects had pressure testing at 9 bilateral sites (18
total) using a hand held dolorimeter (algometer) with a 1
cm2 rubber stopper making contact with the skin (Chatil-
lon, etc.) [1,2]. The degree of pressure required to cause
pain (pain threshold) was recorded at each site, and the
number with pain induced by < 4 kg / cm2 recorded. The
average pressure causing pain was the Average Pain
Threshold. FM and Normal subjects had manual digital
pressure examinations of these points [1,2]. The number
of points that were painful was recorded as Manual Ten-
der Points.
Cerebrospinal fluid (CSF) radioimmunoassays
Lumbar punctures were performed using local anesthetic
and 23G spinal catheters. Volumes of 4 to 8 ml were
obtained, centrifuged, aliquoted, and immediately frozen
at -80°C. Samples were shipped on dry ice to Dr. Lars
Terenius for measurement of neuropeptides. Neuropep-
tides were extracted from 1 ml aliquots using C-18 SepPak
cartridges, eluted, dried, and resuspended for validated
radioimmunoassays for MEAP [13,14] and nociceptin
[15] using the standard methodologies developed in their
laboratory. Concentrations in samples were interpolated
from parallel standard curves. There was insufficient CSF
to use HPLC for precise peptide identification. Hence,
immunoreactive materials (irm) were measured as MEAP-
irm and nociceptin-irm.
Statistics
Geometric mean and 95% confidence intervals were
determined for each neuropeptide, with arithmetic means
and 95% CI's for all other variables. Differences between
groups were assessed by ANOVA. Differences between
means for each pair of groups were assessed by 2-tailed
unpaired Student's t-tests with Bonferroni corrections for
multiple comparisons. Significance was ascribed for p <
0.05.
Results
Demographics
Lumbar punctures were performed on 14 FM (1 male), 10
LBP (5 male) and 6 Normal (2 male) subjects. The aver-
ages and ranges of ages for these 3 groups were similar
(overall average 42.7 yr, 38.8 to 46.6; 95% CI). There were
4 African-Americans in the FM group, and 1 each in the
LBP and Normal groups, and 1 Asian in the FM group. The
remainder was Caucasian.
Systemic complaints questionnaire
Significant differences were found between FM and Nor-
mal results by 2-tailed unpaired Student's t-tests with p <
0.05 after Bonferroni corrections for multiple compari-
sons of this data. All of the FM subjects complained of
fatigue (figure 1). Other highly prevalent individual
Systemic symptoms questionnaire results Figure 1
Systemic symptoms questionnaire results. FM (white bars), 
LBP (grey bars) and Normal (black bars) results are shown 
for each domain. The x-axis shows the systems domains with 
the total number of questions in parentheses. The y-axis 
shows the number of positive responses within each domain. 
The error bars are the 95% confidence intervals. FM scores 
were higher than Normal for ENT and IBS (p ≤ 0.05), Chest, 
Headache, Neurological and Bladder (p ≤ 0.01), Fatigue and 
Musculoskeletal (p ≤ 0.001). FM scores were higher than LBP 
for Neurological (p ≤ 0.05), Chest (p ≤ 0.01) and Fatigue (p ≤ 
0.001). Normal and LBP scores were not different.
SF-36 domain results Figure 2
SF-36 domain results. Scores were ranked Normal (white 
bars with down-going 95%CI) > FM (black bars with up-going 
95%CI) > LBP (grey bars with up-going 95%CI). The Normal 
group had significantly higher scores than FM for EP (p ≤ 
0.05), SF (p ≤ 0.01), PF, PP, E/F, P and GP, but not MH or CH. 
All Normal means were highly significantly greater (p ≤ 
0.001) than all LBP scores. FM scores were higher than LBP 
for EP, GP, and CH (p ≤ 0.05), SF (p ≤ 0.01), and MH and P (p 
≤ 0.001). FM and LBP were not different for PF, PP or E/F.
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symptoms in FM were morning stiffness, muscle pain and
spasms, and difficulties concentrating on cognitive tasks.
FM scores were higher than Normal for ENT and IBS (p <
0.05), Chest, Headache, Neurological and Bladder (p <
0.01), Fatigue and Musculoskeletal (p < 0.001) com-
plaints. When compared to LBP, FM scores were higher for
Neurological (p < 0.05), Chest (p < 0.01) and Fatigue (p
< 0.001) complaints. Normal and LBP scores were not dif-
ferent. Chronic Fatigue Syndrome co-existed with FM in 7
of the 14 subjects compared to none in the LBP and Nor-
mal groups. IBS was present in 58% of FM, 20% of LBP
and 17% of Normal subjects.
SF-36
Domain Scores for the Normal group were all near the
predicted values of 100 (figure 2). FM scores were signifi-
cantly lower for Emotional Problems (p < 0.05), Social
Functioning (p < 0.01), Physical Functioning, Role Limi-
tation due to Physical Problems, Energy / Fatigue, Pain
and General Perception of Health (p < 0.001), but not
Mental Health or Change in Health. All Normal means
were highly significantly greater (p < 0.001) than all LBP
scores. FM scores were higher than LBP for Emotional
Problems, General Perception of Health, and Change in
Health (p < 0.05), Social Functioning (p < 0.01), and
Mental Health and Pain (p < 0.001). FM and LBP were not
different for Physical Functioning, Role Limitation due to
Physical Problems or Energy / Fatigue.
Pain thresholds and tender point counts
Dolorimetry identified significantly lower pressure pain
thresholds for FM (1.51 kg/cm2) compared to the LBP
(2.48 kg/cm2; p < 0.01) and Normal (2.60 kg/cm2; p <
0.001) groups (figure 3). The numbers of tender points
determined by dolorimetry were 9.07 for FM, 3.67 for
LBP, and 1.33 (p < 0.05 vs. FM) for Normal subjects (fig-
ure 4). Digital pressure identified more manual tender
points in FM (13.00; 12.27 to 14.73) than Normal (4.67;
1.00 to 8.34; p < 0.001) groups. An average of 3.8 (1.90 to
5.70) more tender points were detected by manual exam-
inations than by dolorimetry (p < 0.01). This difference
has been attributed to higher anxiety and other
psychometric variables in FM [16]. (Manual tender point
counts were not recorded for LBP subjects.)
Cerebrospinal fluid neuropeptide concentrations
MEAP – irm
The 3 groups had significantly different mean CSF concen-
trations (p = 0.0014, ANOVA). The normal volunteers
had significantly lower geometric mean concentrations
(26.3 pg/ml; 13.9 to 49.9) than the FM (101.7 pg/ml; 72.8
to 142.0; p < 0.01 vs. normal), and LBP (78.0 pg/ml; 51.1
to 119.0; p < 0.05 vs. normal) (figure 5). Co-morbid
Chronic Fatigue Syndrome did not affect the MEAP – irm
results, since the arithmetic means were 112 pg/ml for FM
subjects with this syndrome (n = 7) and 124 pg/ml with
FM alone (n = 6). There were no obvious relationships
with age, gender or race. The small sample size precluded
further statistical analysis of these variables.
Nociceptin – irm was not different between FM (4.27 pg/
ml, 3.22 to 5.66, n = 14), LBP (4.52 pg/ml, 3.12 to 6.55,
n = 10) and Normal (5.65 pg/ml, 2.65 to 12.04, n = 6)
groups.
Systemic pain thresholds and MEAP – irm
These 2 variables were correlated (Pearson's correlation
coefficient of -0.38, p < 0.05; explained variance 0.15)
when all subjects were examined as a single group (figure
6). This correlation was not found when the Normal and
FM groups were examined by themselves. Normal sub-
jects had higher thresholds and lower MEAP – irm con-
centrations. FM subjects had pain thresholds below 2.3
kg/cm2, which was coincidentally the lower 95% CI for
the Normal group. MEAP – irm concentrations had a wide
range in the FM subjects, but the geometric mean was sig-
nificantly higher than for Normal subjects. Pain threshold
and MEAP – irm concentrations did not have linear corre-
lations in either the FM or Normal group. These data sug-
Pressure pain thresholds (kg/cm2) determined by  dolorimetry Figure 3
Pressure pain thresholds (kg/cm2) determined by dolorime-
try. Pain thresholds for FM (triangles) were significantly 
lower than LBP (squares; p = 0.009) and Normal (circles; p = 
0.002) groups. The bars indicated means and 95% confidence 
intervals.
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gested that FM subjects were fundamentally different from
Normal. When the pain threshold was below 2 to 2.3 kg/
cm2, MEAP – irm levels increased approximately 4-fold
compared to Normal. The combination of the widespread
pain, systemic complaints, low pain threshold and high
MEAP – irm concentrations in CSF was distinct from the
low level of symptomatic complaints, normal (high) pain
thresholds, and lower MEAP – irm levels found in the
Normal group.
The LBP group had a chronic regional pain syndrome, no
fibromyalgia, normal pain thresholds and systemic com-
plaints, but severe disability (SF-36 scores). Only the LBP
group showed a linear correlation between pain threshold
and MEAP – irm concentrations (figure 6). The
parameters of this correlation were similar to that of the
entire group. This was due to the overlap of some high
pain threshold / low MEAP – irm LBP subjects with the
Normal group, and low pain threshold / high MEAP – irm
LBP subjects with the FM data. This continuum of pain
threshold and MEAP – irm levels in LBP was different
from the clustered FM and Normal datasets, and sug-
gested a different mechanism of MEAP – irm regulation in
LBP from FM.
Discussion
The Normal group had Systemic Complaints and SF-36
scores in the normal ranges, high pain thresholds, low
numbers of manual and dolorimetry-derived tender
points, and low CSF concentrations of MEAP – irm and
nociceptin – irm.
The LBP group was a positive control for chronic regional
pain. Their Systemic Complaints scores, systemic pain
thresholds and dolorimetry defined tender point counts
were not significantly different from Normal. However,
most of their SF-36 results were near zero indicating the
worst level of impairment of the 3 groups. They were the
only group to show a correlation of decreasing pain
thresholds with increasing MEAP – irm concentrations.
The continuum of MEAP – irm levels in the LBP group led
to borderline significance for the comparison to Normal
levels. Inclusion of LBP subjects with higher or lower pain
Tender points Figure 4
Tender points. The numbers of tender points detected by 
dolorimetry with ≤ 4 kg/cm2 pressure were higher for FM 
(triangles, n = 14), than LBP (squares, n = 9, p = 0.03) and 
Normal (circles, n = 6, p = 0.008) groups. The bars indicated 
means and 95%CI's.
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thresholds may have shifted the MEAP – irm concentra-
tion distribution towards or away, respectively, from the
Normal group results. This is important when comparing
these data to those of other studies. For example, chronic
sciatica patients did not have elevated MEAP – irm com-
pared to controls [33]. However, severity was not graded
as extensively as in our study. Some subjects may have had
less severe low back pain than in our group. If so, then the
linear correlation noted in FIGURE 6 would predict no
significant difference from normal subjects. Conversely,
female LBP subjects with the lowest pain thresholds and
highest MEAP – irm levels may have been making a tran-
sition from chronic low back pain to fibromyalgia [7].
Half of our LBP group was male, introducing gender as a
potentially confounding factor.
The FM group's results were distinctly different from the
Normal and LBP groups. FM had widespread pain
complaints, the highest Systemic Complaints scores, the
lowest pain thresholds, and highest numbers of tender
points of the 3 groups. Their SF-36 scores were
intermediate between LBP and Normal groups. Wide-
spread pain, low pain thresholds, and high Systemic
Complaints scores differentiated FM from Normal and
LBP. CSF MEAP – irm concentrations were approximately
3-fold higher in FM than Normal (figure 5). This con-
firmed earlier findings [14] where a group of women
meeting an older set of fibromyalgia criteria [17,18] had
34% higher CSF MEAP – irm concentrations than a group
of 8 age-matched female control subjects [13]. None of
the FM subjects in the earlier group required analgesics or
other medications suggesting that their symptoms may
have been milder than for our FM group. Our group con-
tained 1 male and 13 females. In contrast, Lui et al. found
MEAP concentrations (peptide identity confirmed by
HPLC) that were 38% lower in FM than control subjects
(p < 0.01) [19]. There was inadequate clinical data to
compare the severity of complaints between these FM
populations. These investigators also used a liquid-liquid
peptide extraction method. The differences in FM severity,
control groups, extraction procedures, and lack of suffi-
cient CSF to identify precise peptides by HPLC [20] made
it difficult to compare these sets of divergent results.
Standardized measurements on CSF withdrawn from
highly characterized and clearly defined subjects and con-
trols will be required to resolve these inconsistencies.
This is the first investigation to examine the potential
effect of co-existing CFS on MEAP – irm levels in FM. This
suggested that the mechanism(s) of CFS were probably
independent of those responsible for the elevated MEAP –
irm levels in FM. Unfortunately, CFS subjects without FM
could not be simultaneously tested to determine if their
MEAP – irm levels were normal (as would be predicted).
Nociceptin – irm levels were the same in our three groups.
The levels were about 10% of that found in women during
labor [21]. It was unclear if the higher concentrations were
due to pregnancy, neurohormonal adaptations during
labor and delivery, or the effects of acute pain. Again, the
absence of a control group comparable to our pain-free
Normal group makes mechanistic comparisons difficult.
Conclusions
The Normal group had Systemic Complaints and SF-36
scores in the normal ranges, high pain thresholds, low
numbers of manual and dolorimetry-derived tender
points and low cerebrospinal fluid MEAP and nociceptin
concentrations. The LBP chronic regional pain group had
similar Systemic Complaints scores, systemic pain thresh-
olds and dolorimetry-defined tender point counts. How-
ever, most of their SF-36 results were near zero indicating
the worst level of impairment of the 3 groups. MEAP – irm
was just significantly elevated compared to the Normal
group, and was correlated to the systemic pain threshold.
The FM group was distinct since they had widespread pain
complaints, the highest Systemic Complaints scores, the
lowest pain thresholds, and highest numbers of tender
points of the 3 groups. Their SF-36 scores were intermedi-
ate between the LBP and Normal groups. MEAP – irm con-
centrations were significantly higher in the FM than
Semi-logarithmic relationships between pain thresholds and  MEAP Figure 6
Semi-logarithmic relationships between pain thresholds and 
MEAP. FM subjects (black triangles) had pain thresholds 
below 2.3 kg/cm2 (heavy, black error bars). Normal subjects 
(grey circles, cabled grey error bars) had lower MEAP and 
higher pain thresholds compared to FM. LBP subjects (open 
diamonds) had results that covered the full ranges for both 
variables (upper right error bars). The data for all subjects 
were linearly correlated (Pearson's correlation coefficient R 
= -0.38, p < 0.05) with an explained variance (R2) of 0.15. 
The line appears curved on this semi-logarithmic plot.
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Normal group. The co-existence of Chronic Fatigue
Syndrome with FM did not alter the MEAP – irm concen-
trations. This suggested that Chronic Fatigue Syndrome
mechanism(s) did not involve preproenkephalin dysfunc-
tion. Nociceptin – irm levels were not different between
these groups, and were lower than previously reported
results from pregnant women in labor. Significant differ-
ences in MEAP – irm concentrations from previous studies
may be due to the highly controlled definition of patients
in this study, selection of control groups, and differences
in peptide extraction methods.
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